Observing safety and effectiveness of Zepzelca for lung cancer
Part of Cancer clinical trials.
This study tracks how safe and effective the drug Zepzelca (a chemotherapy) is for people with advanced small cell lung cancer that has not responded to earlier platinum-based chemo. It allows patients to receive the drug as part of their normal care while researchers collect data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called small cell lung cancer (SCLC) that has spread.
- You have already tried platinum-based chemo (like cisplatin or carboplatin) and it did not work anymore.
- You are scheduled to receive or have already received the study drug Zepzelca.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You are not taking part in any other clinical trial right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This Phase 1 trial tests whether blocking an enzyme (with an acetazolamide-like medicine) can be safely combined with standard treatment for small cell lung cancer that has not spread. The goal is to see if the treatment can be given safely and to learn early signs of benefit.
This trial tests different experimental drugs matched to the specific genetic makeup of your small cell lung cancer. The goal is to see if targeting your cancer's particular molecular type can shrink tumors or delay their growth better than standard care.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
Hear when a new SCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.